Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab
- PMID: 29976649
- DOI: 10.1183/13993003.01025-2018
Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab
Conflict of interest statement
Conflict of interest: D.J. Allen reports non-financial support from Mundipharma for attendance at the ERS meeting, and speaker fees for presenting at an educational meeting sponsored by Astra Zeneca, outside the submitted work. Conflict of interest: L-J. Holmes reports personal fees for speaking at conferences from Novartis and TEVA, outside the submitted work.
Comment on
-
Nonadherence in the era of severe asthma biologics and thermoplasty.Eur Respir J. 2018 Apr 4;51(4):1701836. doi: 10.1183/13993003.01836-2017. Print 2018 Apr. Eur Respir J. 2018. PMID: 29519922 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical